MEDPLUS.NS(MEDPLUS.NS)
MEDPLUS.NS
No analyst ratings available
No analyst price targets available for MEDPLUS.NS
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|
| Revenue Avg | $80.52B | $92.09B | $105.11B | $117.00B |
| Low | $79.28B | $89.78B | $104.90B | $115.10B |
| High | $81.53B | $95.79B | $105.32B | $119.51B |
| EBITDA Avg | $12.45B | $14.24B | $16.26B | $18.10B |
| Low | $12.26B | $13.89B | $16.23B | $17.80B |
| High | $12.61B | $14.82B | $16.29B | $18.49B |
| EBIT Avg | $6.52B | $7.46B | $8.51B | $9.47B |
| Low | $6.42B | $7.27B | $8.49B | $9.32B |
| High | $6.60B | $7.76B | $8.53B | $9.68B |
| Net Income Avg | $2.05B | $2.90B | $4.31B | — |
| Low | $1.83B | $2.16B | $3.42B | — |
| High | $2.34B | $3.78B | $5.19B | — |
| EPS Avg | $17.28 | $26.97 | $35.87 | — |
| Low | $15.20 | $17.95 | $28.49 | — |
| High | $19.47 | $31.51 | $43.24 | — |
| Analysts (Rev / EPS) | 5 / 4 | 6 / 5 | 2 / 2 | 1 / — |
| Metric | Q3 2026 |
|---|---|
| Revenue Avg | $18.96B |
| Low | $18.96B |
| High | $18.96B |
| EBITDA Avg | $2.93B |
| Low | $2.93B |
| High | $2.93B |
| EBIT Avg | $1.54B |
| Low | $1.54B |
| High | $1.54B |
| Net Income Avg | — |
| Low | — |
| High | — |
| EPS Avg | — |
| Low | — |
| High | — |
| Analysts (Rev / EPS) | 3 / — |